Amneal Gets FDA OK for First Generic of Merck's NuvaRing
December 12 2019 - 8:04AM
Dow Jones News
By Colin Kellaher
Amneal Pharmaceuticals Inc. (AMRX) Thursday said it received
U.S. Food and Drug Administration approval for EluRyng, the first
generic version of Merck & Co.'s (MRK) NuvaRing
contraceptive.
The Bridgewater, N.J., pharmaceutical company said it has
initiated commercialization activities for EluRyng, which it is
manufacturing internally and launching Thursday.
NuvaRing had U.S. sales of about $976 million for the 12 months
ended Oct. 31, Amneal said, citing healthcare data and analytics
provider Iqvia.
Shares of Amneal, which closed Wednesday at $3.48, jumped nearly
17% in premarket trading Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 12, 2019 07:49 ET (12:49 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024